Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (521-530 of 633) with videos related to

Pageof 64
Sort By:
Hepatology (Baltimore, Md.)|October 31, 2015
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infectionMaria Antonella Burza, Benedetta Maria Motta, Rosellina Margherita Mancina, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseYun-Fan Liaw, I-Shyan Sheen, Chuan-Mo Lee, et al.
Journal of Hepatology|November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ programThierry Poynard, Mona Munteanu, Massimo Colombo, et al.
Molecular Systems Biology|January 12, 2024
Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver diseaseSebastian Burbano de Lara, Svenja Kemmer, Ina Biermayer, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Alimentary Pharmacology & Therapeutics|January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitisMaurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2022
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenibOsman Öcal, Kerstin Schütte, Christoph J Zech, et al.
Journal of Clinical Medicine|December 8, 2019
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV InfectionChristiana Graf, Antonia Mondorf, Viola Knop, et al.
Digestive Diseases and Sciences|March 24, 2018
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune HepatitisCumali Efe, Haider Al Taii, Henriette Ytting, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Pageof 64

Showing results (521-530 of 633) with videos related to

Sort By:
Pageof 64
Hepatology (Baltimore, Md.)|October 31, 2015
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infectionMaria Antonella Burza, Benedetta Maria Motta, Rosellina Margherita Mancina, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver diseaseYun-Fan Liaw, I-Shyan Sheen, Chuan-Mo Lee, et al.
Journal of Hepatology|November 9, 2010
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ programThierry Poynard, Mona Munteanu, Massimo Colombo, et al.
Molecular Systems Biology|January 12, 2024
Basal MET phosphorylation is an indicator of hepatocyte dysregulation in liver diseaseSebastian Burbano de Lara, Svenja Kemmer, Ina Biermayer, et al.
The Lancet. Infectious Diseases|March 26, 2013
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trialKatja Deterding, Norbert Grüner, Peter Buggisch, et al.
Alimentary Pharmacology & Therapeutics|January 19, 2021
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitisMaurizia R Brunetto, Ivana Carey, Benjamin Maasoumy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2022
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenibOsman Öcal, Kerstin Schütte, Christoph J Zech, et al.
Journal of Clinical Medicine|December 8, 2019
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV InfectionChristiana Graf, Antonia Mondorf, Viola Knop, et al.
Digestive Diseases and Sciences|March 24, 2018
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune HepatitisCumali Efe, Haider Al Taii, Henriette Ytting, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Pageof 64